1.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000454401, GERCOR-TAUROX, SANOFI-GERCOR-TAUROX, EU-20573, NCT00274885
|
|
2.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CAP001, PDDG/CAP001, NCT00854477
|
|
3.
|
Phase: Phase IV Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: RaMM-BO 2.0, NCT01041612
|
|
4.
|
Phase: Phase IV Type: Treatment Status: Active Age: 19 to 70 Sponsor: Other Protocol IDs: SNUBH-GS-HBP2, B-0712-052-006 (local IRB), NCT01111591
|
|
5.
|
Phase: Phase IV Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: A6181202, NCT01525550
|
|
6.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 79 Sponsor: Pharmaceutical / Industry Protocol IDs: AMT/P2CA/001, LC003AURON2005, NCT00332280
|
|
7.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 20 to 85 Sponsor: Other Protocol IDs: AMC0183, NCT00689715
|
|
8.
|
Phase: Phase III, Phase II Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: CDR0000675485, PACT-15, 2010-019942-23, SRSI-PACT-15, EU-21040, NCT01150630
|
|
9.
|
Phase: Phase III, Phase II Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 04-22, 11PAN01, NCT01360853
|
|
10.
|
Phase: Phase III, Phase II Type: Supportive care, Treatment Status: Approved-not yet active Age: Not specified Sponsor: Other Protocol IDs: TJ20111123, NCT01598584
|
|
11.
|
Phase: Phase III Type: Treatment Status: Active Age: Over 18 Sponsor: Other Protocol IDs: CRUK-TELOVAC-V4, EUDRACT-2006-000461-10, EU-20683, ISRTCN43482138, NCT00425360, TELOVAC
|
|
12.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: TASMC-07-NA-132-CTIL, NCT00486460
|
|
13.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000564099, IPC-BAYPAN, INCA-RECF0426, IPC-2005-006, BAYPAN, NCT00541021
|
|
14.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: CDR0000589283, GERCOR-LAP-07-D07-1, EU=20827, ROCHE-GERCOR-LAP-07-D07-1, EudraCT- 2007-001174-81, NCT00634725
|
|
15.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: 18 to 80 Sponsor: Other Protocol IDs: CDR0000593019, GERCOR-PAM07-D07-2, EUDRACT 2007-002115-59, EU-20837, PFIZER-GERCOR-PAM07-D07-2, NCT00662688
|
|
16.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: RTOG-0848, RTOG 0848, NCT01013649
|
|
17.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: NLG0405, OBA# 0912-1013, NCT01072981
|
|
18.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 75 Sponsor: Other Protocol IDs: 115-09, 2008-004802-14, AIO-PAK-0111, NCT01077427
|
|
19.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: OXALI_L_04918, U1111-1116-9746, NCT01121848
|
|
20.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NEOPAC, NCT01314027
|
|
21.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NNR-7, NCT01332773
|
|
22.
|
Phase: Phase III Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: NCT-2008-11-03-1018, 60516908, NCT01362582
|
|
23.
|
Phase: Phase III Type: Treatment Status: Approved-not yet active Age: 18 and over Sponsor: Other Protocol IDs: NetPac, NCT01419002
|
|
24.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: MM-398-07-03-01, NCT01494506
|
|
25.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 79 Sponsor: Other Protocol IDs: prodige/accord 24, NCT01526135
|